{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:51:02Z","timestamp":1784631062125,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"DOI":"10.1186\/s12969-025-01057-8","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T10:41:46Z","timestamp":1737628906000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Frequency of remission achievement in the pre-treat-to-target decade in juvenile idiopathic arthritis"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3973-3442","authenticated-orcid":false,"given":"Ana Isabel","family":"Rebollo-Gim\u00e9nez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Pistorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Maria","family":"Orsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ridella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Aldera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Carlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Natoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Burrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Rosina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Naddei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Consolaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperanza","family":"Naredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Ravelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"1057_CR1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nrrheum.2013.105","volume":"9","author":"DJ Lovell","year":"2013","unstructured":"Lovell DJ, Ruperto N, Giannini EH, Martini A. Advances from clinical trials in juvenile idiopathic arthritis. Nat Rev Rheumatol. 2013;9:557.","journal-title":"Nat Rev Rheumatol"},{"key":"1057_CR2","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13075-019-1950-7","volume":"21","author":"G Giancane","year":"2019","unstructured":"Giancane G, Muratore V, Marzetti V, Quilis N, Benavente BS, Bagnasco F, et al. Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era. Arthritis Res Ther. 2019;21:168.","journal-title":"Arthritis Res Ther"},{"key":"1057_CR3","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1136\/annrheumdis-2018-213030","volume":"77","author":"A Ravelli","year":"2018","unstructured":"Ravelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2018;77:819.","journal-title":"Ann Rheum Dis"},{"key":"1057_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/annrheumdis-2018-213902","volume":"78","author":"P Hissink Muller","year":"2019","unstructured":"Hissink Muller P, Brinkman DMC, Schonenberg-Meinema D, van den Bosch WB, Koopman-Keemink Y, Brederije ICJ, et al. Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial. Ann Rheum Dis. 2019;78:51.","journal-title":"Ann Rheum Dis"},{"key":"1057_CR5","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1136\/annrheumdis-2019-216843","volume":"79","author":"A Klein","year":"2020","unstructured":"Klein A, Minden K, Hospach A, Foeldvari I, Weller-Heinemann F, Trauzeddel R, et al. Treat-to-target study for improved outcome in polyarticular juvenile idiopathic arthritis. Ann Rheum Dis. 2020;79:969.","journal-title":"Ann Rheum Dis"},{"key":"1057_CR6","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1002\/art.40865","volume":"71","author":"NM Ter Haar","year":"2019","unstructured":"Ter Haar NM, van Dijkhuizen EHP, Swart JF, van Royen-Kerkhof A, El Idrissi A, Leek AP, et al. Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study. Arthritis Rheumatol. 2019;71:1163.","journal-title":"Arthritis Rheumatol"},{"key":"1057_CR7","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390.","journal-title":"J Rheumatol"},{"key":"1057_CR8","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.3899\/jrheum.091474","volume":"37","author":"G Filocamo","year":"2010","unstructured":"Filocamo G, Dav\u00ec S, Pistorio A, Bertamino M, Ruperto N, Lattanzi B, et al. Evaluation of 21-numbered circle and 10-centimeter horizontal line visual analog scales for physician and parent subjective ratings in juvenile idiopathic arthritis. J Rheumatol. 2010;37:1534.","journal-title":"J Rheumatol"},{"key":"1057_CR9","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3899\/jrheum.080432","volume":"36","author":"A Bazso","year":"2009","unstructured":"Bazso A, Consolaro A, Ruperto N, Pistorio A, Viola S, Magni-Manzoni S, et al. Development and testing of reduced joint counts in juvenile idiopathic arthritis. J Rheumatol. 2009;36:183.","journal-title":"J Rheumatol"},{"key":"1057_CR10","unstructured":"Wallace CA, Ruperto N, Giannini E, Childhood Arthritis and Rheumatology Research Alliance, Pediatric Rheumatology International Trials Organization, Pediatric Rheumatology Collaborative Study Group. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol. 2004; 31:2290."},{"key":"1057_CR11","doi-asserted-by":"publisher","first-page":"426","DOI":"10.55563\/clinexprheumatol\/rxidz4","volume":"39","author":"C Bava","year":"2021","unstructured":"Bava C, Mongelli F, Pistorio A, Bertamino M, Bracciolini G, Dalpr\u00e0 S, et al. Analysis of arthritis flares after achievement of inactive disease with methotrexate monotherapy in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2021;39:426.","journal-title":"Clin Exp Rheumatol"},{"key":"1057_CR12","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12969-019-0355-0","volume":"17","author":"C Bava","year":"2019","unstructured":"Bava C, Mongelli F, Pistorio A, Bertamino M, Bracciolini G, Dalpr\u00e0 S, et al. A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2019;17:50.","journal-title":"Pediatr Rheumatol Online J"},{"key":"1057_CR13","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1002\/art.24202","volume":"59","author":"N Solari","year":"2008","unstructured":"Solari N, Viola S, Pistorio A, Magni-Manzoni S, Vitale R, Ruperto N, et al. Assessing current outcomes of juvenile idiopathic arthritis: a cross-sectional study in a tertiary center sample. Arthritis Rheum. 2008;59:1571.","journal-title":"Arthritis Rheum"},{"key":"1057_CR14","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/art.30076","volume":"63","author":"A Ravelli","year":"2011","unstructured":"Ravelli A, Varnier GC, Oliveira S, Castell E, Arguedas O, Magnani A, et al. Antinuclear antibody-positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. Arthritis Rheum. 2011;63:267.","journal-title":"Arthritis Rheum"},{"key":"1057_CR15","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/acr.23709","volume":"71","author":"K Minden","year":"2019","unstructured":"Minden K, Horneff G, Niewerth M, Seipelt E, Aringer M, Aries P, et al. Time of Disease-Modifying Antirheumatic Drug Start in Juvenile Idiopathic Arthritis and the Likelihood of a Drug-Free Remission in Young Adulthood. Arthritis Care Res (Hoboken). 2019;71:471.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1057_CR16","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/acr.24857","volume":"74","author":"M Glerup","year":"2022","unstructured":"Glerup M, Arnstad ED, Rypdal V, Peltoniemi S, Aalto K, Rygg M, et al. Changing Patterns in Treatment, Remission Status, and Categories in a Long-Term Nordic Cohort Study of Juvenile Idiopathic Arthritis. Arthritis Care Res (Hoboken). 2022;74:719.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1057_CR17","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s13075-023-03166-9","volume":"25","author":"F Oliveira Ramos","year":"2023","unstructured":"Oliveira Ramos F, Rodrigues AM, Melo AT, Aguiar F, Brites L, Azevedo S, et al. Influence of the timing of biological treatment initiation on Juvenile Idiopathic Arthritis long-term outcomes. Arthritis Res Ther. 2023;25:177.","journal-title":"Arthritis Res Ther"},{"key":"1057_CR18","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1136\/annrheumdis-2014-205372","volume":"74","author":"J Guzman","year":"2015","unstructured":"Guzman J, Oen K, Tucker LB, Huber AM, Shiff N, Boire G, et al. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum Dis. 2015;74:1854.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1057_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000074","volume":"8","author":"C Sengler","year":"2015","unstructured":"Sengler C, Klotsche J, Niewerth M, Liedmann I, F\u00f6ll D, Heiligenhaus A, et al. The majority of newly diagnosed patients with juvenile idiopathic arthritis reach an inactive disease state within the first year of specialised care: data from a German inception cohort. RMD Open. 2015;8(1): e000074.","journal-title":"RMD Open"},{"key":"1057_CR20","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.semarthrit.2017.05.007","volume":"47","author":"SJW Shoop-Worrall","year":"2017","unstructured":"Shoop-Worrall SJW, Kearsley-Fleet L, Thomson W, Verstappen SMM, Hyrich KL. How common is remission in juvenile idiopathic arthritis: A systematic review. Semin Arthritis Rheum. 2017;47:331\u20137.","journal-title":"Semin Arthritis Rheum"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-025-01057-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-025-01057-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-025-01057-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T10:41:52Z","timestamp":1737628912000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-025-01057-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1057"],"URL":"https:\/\/doi.org\/10.1186\/s12969-025-01057-8","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"4 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee of Regione Liguria (Genoa, Italy) under protocol number 642\/2022\u2014DB id 12828, dated 16 June 2023.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}